Public Health Bulletin on HIV and STIs in the Île-de-France Region. December 2021.

Published on 1 December 2021

Key points

Participation in the LaboVIH survey and accurate reporting of new HIV diagnoses via e-DO by clinicians and laboratory technicians are essential for producing reliable surveillance indicators. In 2020, due to the health crisis, this was not the case in all regions, particularly in Île-de-France. A LaboVIH participation rate of 52% did not allow for an estimate of the rate of serological tests performed or the rate of positive serological tests. The detection rate, at 165 (141–188) per million inhabitants, should be interpreted with caution due to the very wide confidence interval.

In 2020, regardless of the STI, a decline in the screening rate (for both men and women) was observed in Île-de-France as well as at the national level. These screening rates were lower compared to 2019. Syphilis: 57.6 per 1,000 inhabitants; Chlamydia trachomatis infections: 52.5 per 1,000 inhabitants; Gonococcal infections: 48.3 per 1,000 inhabitants.

CeGIDD participation declined in Île-de-France in 2020 (39%) compared to 2018 (42%). Positivity rates were higher among men than among women: Gonococcal infections: 0.1% among women and 0.8% among men; Syphilis: 1.8% among women and 10% among men.

Data from the Sex Survey were used in this bulletin to document screening participation. Over the 12 months preceding the survey, the screening rate was 48% for all participants and 51.6% for the sample of men who have sex with men.